Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2007

View Archived Issues

Preclinical and clinical data on novel inhibitors of HCV NS5B polymerase and NS3 proteases

Clinical studies of bifeprunox presented

Snapshots of drugs being evaluated for schizophrenia

Recent patents impart new treatments for cardiovascular disorders

New treatment options for inflammatory disorders reported in recent patents

In vitro and in vivo characterization of an orally active VEGF/PDGF inhibitor

New therapeutic agents for cancer covered in recent patent literature

AZD-7762, a potent and selective Chk kinase inhibitor, potentiates activity of DNA-damaging agents

Novel Met inhibitor from Pfizer with potential in osteosarcoma

First-in-class non-ATP-selective Src inhibitor designed by Kinex

Phase I results in cancer patients reported for CDK inhibitor P-276-00

FDA grants orphan drug status to ganciclovir for acute herpetic keratitis

Clearance for phase I Japanese study of nimotuzumab for solid tumors

Inecalcitol shows high level of tolerance in phase I trial

SPRC-AB01 granted fast track status for chronic sinusitis

KD-7040 begins second phase I study for neuropathic pain

Phase III confirmatory study of DX-88 for HAE begins treatment

New Zealand regulator approves phase I/IIa study of DiabeCell

Indevus and Valera complete merger

Alnylam to advance ALN-VSP01 for liver cancer

FDA licenses first U.S. avian influenza vaccine for humans

Polyphenon E Ointment accepted for review in Germany, Austria, and Spain

Neupro studied for sleep problems, early morning motor symptoms in Parkinson's

Prevascar improves scar appearance following incisional wounds

Biliary fibrosis aggravated by the antiangiogenic alpha(v)beta(3) antagonist cilengitide in rats

Arixtra approved in Japan

Japanese approval for Alvesco

Uritos approved for overactive bladder in Japan

Valtrex approved in Japan for pediatric varicella

Zetia approved in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...